clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Koh WJ et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. 2017 Clin. Infect. Dis. pmid:28011608
Çekin AH et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. 2017 Turk J Gastroenterol pmid:28007678
Ikeue T et al. Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. 2017 Intern. Med. pmid:28924121
Yamamoto S et al. Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. 2017 Biochem. Biophys. Res. Commun. pmid:27998764
Panozzo C et al. Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. 2017 Biochim. Biophys. Acta pmid:28888990
Santos MA et al. Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. 2017 Am. J. Med. pmid:27984010
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Hiroi S et al. Impact of health insurance coverage for gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. 2017 BMJ Open pmid:28760790
Stieler Stewart AL et al. Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. 2017 Equine Vet. J. pmid:28238211
Emmanuel R et al. Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. 2017 Microb. Pathog. pmid:29101061
Bichler EK et al. Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling. 2017 J. Neurophysiol. pmid:27733592
Gouin-Thibault I et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017 J. Thromb. Haemost. pmid:27893182
Tsugawa K et al. Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells. 2017 Clin. Exp. Nephrol. pmid:27614743
Park J et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Clin. Infect. Dis. pmid:28011609
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Okuda M et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. 2017 Pediatr Int pmid:27223686
Bewick J et al. The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. 2017 Clin Otolaryngol pmid:27223120
Chang KH et al. Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. 2017 J. Matern. Fetal. Neonatal. Med. pmid:27687157
Chew CA et al. The diagnosis and management of H. pylori infection in Singapore. 2017 Singapore Med J pmid:28536725
Gunnarsdottir AI et al. Antibiotic susceptibility of Helicobacter pylori in Iceland. 2017 Infect Dis (Lond) pmid:28440099
Manniello MD et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility. 2017 Int J Pharm pmid:28377314
Van der Paardt AL et al. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. 2017 Eur. Respir. J. pmid:28331034
Radzikowska E et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. 2017 PLoS ONE pmid:28945804
Chew KL et al. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. 2017 J. Med. Microbiol. pmid:28874233
Miura S et al. [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation]. 2017 Gan To Kagaku Ryoho pmid:28860442
McCallum GB et al. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. 2017 Cochrane Database Syst Rev pmid:28828759
Turvey SL et al. Mycobacterium branderi infection: Case report and literature review of an unusual and difficult-to-treat non-tuberculous mycobacterium. 2017 Int. J. Infect. Dis. pmid:28268125
Kadota JI et al. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. 2017 J. Infect. Chemother. pmid:28254517
Ufuk A et al. In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. 2017 Mol. Pharm. pmid:28252969
Quinn KL et al. Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. 2017 Drug Saf pmid:28421551
Ramzy I et al. GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. 2016 Rev. Inst. Med. Trop. Sao Paulo pmid:27982354
Noda H et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. 2016 J Gastrointestin Liver Dis pmid:27689190
Giorgio F et al. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. 2016 Scand. J. Gastroenterol. pmid:27687850
Donzelli A Helicobacter pylori Eradication? 2016 Gastroenterology pmid:27590693
Christl I et al. Clarithromycin and Tetracycline Binding to Soil Humic Acid in the Absence and Presence of Calcium. 2016 Environ. Sci. Technol. pmid:27438991
Luo XF et al. Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. 2016 World J. Gastroenterol. pmid:27433095
Sakurai Y et al. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. 2016 Adv Ther pmid:27432383
Hirasawa K et al. Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. 2016 PLoS ONE pmid:27977675
Mougari F et al. Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. 2016 Expert Rev Anti Infect Ther pmid:27690688
Laird-Fick HS et al. Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts. 2016 Postgrad Med J pmid:27222587
Phiphatpatthamaamphan K et al. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. 2016 Asian Pac. J. Cancer Prev. pmid:27221874
Kim SY et al. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report. 2016 BMC Infect. Dis. pmid:27188784
Klesiewicz K et al. Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. 2016 J. Antibiot. pmid:27025351
Kawashima K et al. Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. 2016 Dig Liver Dis pmid:27012448
Miyamoto S et al. Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. 2016 Tumour Biol. pmid:26825980
Bohnert JA et al. Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. 2016 Antimicrob. Agents Chemother. pmid:26824939
Topp E et al. Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. 2016 Sci. Total Environ. pmid:27096634
Boyanova L et al. Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. 2016 Microb. Drug Resist. pmid:26618567
Shin WG et al. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. 2016 Helicobacter pmid:26470999
Liou JM et al. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of in the community and hospital populations: a randomised trial. 2016 Gut pmid:26338825